Targeted therapies have yet to have significant impact on the survival of patients with bladder cancer. In this study, we focused on the urea cycle enzyme argininosuccinate synthetase (ASS1) as a therapeutic target in bladder cancer, based on our discovery of the prognostic and functional import of ASS1 in this setting. ASS1 expression status in bladder tumors from 183 Caucasian and 295 Asian patients was analyzed, along with its hypothesized prognostic impact and association with clinicopathological features including tumor size and invasion. Further, the genetics, biology and therapeutic implications of ASS1 loss were investigated in urothelial cancer cells. We detected ASS1 negativity in 40% of bladder cancers, where multivariate analysis indicated worse disease-specific and metastasis-free survival. ASS1 loss secondary to epigenetic silencing was accompanied by increased tumor cell proliferation and invasion, consistent with a tumor suppressor role for ASS1. In developing a treatment approach, we identified a novel targeted antimetabolite strategy to exploit arginine deprivation with pegylated arginine deiminase (ADI-PEG20) as a therapeutic. ADI-PEG20 was synthetically lethal in ASS1-methylated bladder cells and its exposure was associated with a marked reduction in intracellular levels of thymidine, due to suppression of both uptake and de novo synthesis. We found that thymidine uptake correlated with thymidine kinase-1 protein levels, and that thymidine levels were imageable with [18F]-fluoro-L-thymidine (FLT)-positron emission tomography (PET). In contrast, inhibition of de novo synthesis was linked to decreased expression of thymidylate synthase and dihydrofolate reductase. Notably, inhibition of de novo synthesis was associated with potentiation of ADI-PEG20 activity by the antifolate drug pemetrexed. Taken together, our findings argue that arginine deprivation combined with antifolates warrants clinical investigation in ASS1-negative urothelial and related cancers, using FLT-PET as an early surrogate marker of response. 
Introduction
Urothelial carcinoma is the fourth most common malignancy diagnosed in men, and the seventh commonest cause of solid cancer-related death in the US, accounting for 15, 000 deaths per annum (1) . The 5-year overall survival rate of 40-60% for muscle invasive bladder cancer has plateaued over the last three decades, in part, due to the frequent comorbidities in this patient group (2) . Moreover, despite $4.0 billion spent each year on bladder cancer treatment in the US alone -one of the highest expenditures in oncology -targeted therapies have been ineffective to date in this disease (3) .
Recently, arginine auxotrophy or the absolute requirement for exogenous arginine for cellular growth has been detected in several chemoresistant solid cancers including hepatocellular carcinoma, melanoma, mesothelioma, and prostate cancer (4) (5) (6) . Arginine fuels an array of biosynthetic reactions including proteins, nitric oxide (NO), polyamines, agmatine, and the amino acids proline and glutamate and therefore may modulate tumorigenesis at multiple levels (7) . Inactivation of the pleiotropic enzyme, argininosuccinate synthetase 1 (ASS1), with key roles in the urea cycle, citrulline-NO cycle and arginine biosynthesis has emerged as a principal driver of tumoral arginine auxotrophy, with evidence for epigenetic silencing and HIF-1alpha-mediated transcriptional repression of ASS1 (5, 8, 9) . Significantly, ASS1 loss has been associated with decreased overall survival in ovarian cancer and myxofibrosarcoma, and reduced metastasis-free survival in osteosarcoma implicating a tumor suppressor function for this metabolic gene (10) (11) (12) . Thus, arginine deprivation is being tested increasingly in the clinic, modelled on the successful introduction of another amino acid depletor, namely asparaginase, in the management of acute lymphoblastic leukemia five decades ago (13) . Specifically, 6 several early phase trials of the arginine-degrading mycoplasmal enzyme, pegylated arginine deiminase (ADI-PEG20) have led to phase II/III randomized studies in melanoma, hepatocellular cancer and mesothelioma (14) (15) (16) .
Here, we characterized ASS1 in bladder cancer based on the fact that loss of chromosome 9, including q34 the locus of ASS1, is a known early event in urothelial tumorigenesis (17) . Previously, Linnenbach et al provided evidence for a truncation mutation at the ASS1 locus in a ureteric carcinoma sample, while searching for tumor suppressors at 9q34 (18) . Here, we show that ASS1 negativity is a common event in bladder cancer detected in ~40% of tumors by immunohistochemistry.
Furthermore, to address a putative tumor suppressor role, we performed additional genetic and epigenetic studies of ASS1 using a panel of bladder cancer cell lines.
Finally, we studied the therapeutic consequences of ASS1 loss in bladder cancer, identifying a novel targeted antimetabolite strategy that combines arginine deprivation with the antifolate, pemetrexed. These studies were reinforced by metabolomic and positron emission tomography (PET) tracer analyses, which identify intracellular thymidine levels as a novel biomarker of early treatment response.
Materials and Methods

Primary tumor characteristics
Tissue microarrays (TMAs) were constructed using a training set of biopsy samples, comprising 183 urothelial carcinomas collected at the Cancer Research UK Cambridge Research Institute (19) , and an independent test set of 295 urothelial carcinomas, which were resected consecutively with curative intent in Chi Mei 
Immunohistochemistry
ASS1 immunohistochemistry was performed using liver control sections as described previously (5) . The scoring of TS (1:100, Clone EPR4545, Epitomics, CA) and DHFR (1:100, Clone: EPR5285, Epitomics, CA) was performed using an H-score, determined by the percentage and intensity of positively stained tumor cells with cases stratified according to high (no less than the median score) or low expression (less than the median score) (20) .
Cell lines and culture
Six bladder cancer cell lines were grown in a humidified atmosphere at 37 o C and 5% CO 2 in endotoxin-free RPMI medium with 10% fetal bovine serum (RT112, 5637, SCaBER, 253J, T24) or DMEM with 10% fetal bovine serum (UMUC3). The arginine concentration was ~10-fold higher in the culture medium compared to that 
Methylation specific PCR (MSP)
1μg of genomic DNA was modified with Sodium Bisulphite using the EZ DNA methylation kit (Zymo, CA, USA) according to the manufacturer's instructions. 50ng of modified DNA was amplified using the following primers designed using the 
Pyrosequencing
Methylation in the CpG islands of the ASS1 gene in the urothelial cell line panel was also analyzed using pyrosequencing technology. For pyrosequencing of the paraffin primary bladder cancer samples, PCR amplification and sequencing primers were optimized using PyroMark Assay Design Software 2.0. Details of PCR primers and conditions are available on request.
Sequencing analysis
The coding exons and flanking sequences of ASS1 were analyzed by Sanger 
ASS1 overexpression and knockdown
ASS1 overexpression was performed in 253J, UMUC-3 and T24 bladder cancer cells using ASS1pIREShyg3 (or control) vector under hygromycin (200 μg/ml) selection, as described previously (10) . ASS1 knockdown in 5637 bladder cancer cells was performed using the pSilencer 4.1-CMVpuro vector (Ambion, Paisley, UK) containing short hairpin RNA (shRNA) sequences targeting ASS1 (SMARTpool, Dharmacon) or a non-targeting control shRNA under puromycin (1 μg/ml) selection.
Proliferation assays
Briefly, 3x10 4 
Immunoblotting
Western blotting for ASS1 (BD Biosciences, UK) was performed as described previously (5) . Membranes were also probed for TS (Sigma-Aldrich, UK), DHFR, TK1 (Abcam, UK), p53R2 (Santa Cruz Biotechnology, US), PARP (Signal Transduction), β-actin and Hsc70.
Drug treatments
Arginine depletion experiments were performed using ADI-PEG20 (Polaris Group, Technology) and annexin V staining (21) . Proteosome inhibition and demethylation experiments were performed using MG132 (1 μM, Sigma-Aldrich, UK) and 5-aza-2'-deoxycytidine (5-Aza-dC, 0.1-1 μM, Sigma-Aldrich, UK), respectively.
Liquid chromatography-mass spectrometry (LC/MS)
PBS control and ADI-PEG20 treated cells (3 × 10 6 ) were washed twice with phosphate buffer saline and then harvested by adding 10 mL of ice cold 80% methanol containing 0.1% formic acid (all reagents from Fisher Scientific, UK). Cell extracts were prepared using a standard protocol and injected into the liquid chromatography-mass spectrometry (LC-MS) system. LC was performed using the nanoACQUITY UltraPerformance (UP) LC system (Waters, UK) and MS was 
In vitro tracer uptake assays
Cells were plated at 1 x 10 5 cells per well the evening before the experiment. The next day cells were incubated with ADI-PEG20 (750ng/ml). On the day of the assay, the drug media was removed and incubated in media supplemented with 2% dialyzed fetal bovine serum for 1 hr. 
Results
Loss of ASS1 confers poor survival in bladder cancer
First, we screened for ASS1 expression in a training set bladder cancer TMA derived from a European population revealing that 45% (83/183) of biopsies were ASS1-negative. The validation TMA (Fig. 1A-F 
Methylated ASS1 is linked to increased proliferation and invasion of bladder cancer cells
To understand the regulation of ASS1 expression and its role in urothelial malignancy we screened six bladder carcinoma cell lines for genomic and epigenetic alterations. FISH analysis confirmed all lines were either triploid or tetraploid with the ASS1 locus intact (data not shown). There were no mutations in ASS1 and no loss of heterozygosity in the region immediately surrounding ASS1 (data not shown).
Instead, the UMUC-3 and 253J cell lines were fully methylated while the T24 line was partially methylated at the ASS1 promoter, with negligible ASS1 mRNA and no ASS1 protein. In contrast, all the ASS1-unmethylated cell lines (SCaBER, RT112, and 5637) expressed ASS1 mRNA and protein ( Fig. 2A) . Notably, ASS1 promoter methylation was greatest in UMUC-3 and 253J compared to the T24 cell line by To determine the correlation between immunohistochemical expression of ASS1 and methylation status, tissue blocks of an independent set of 30 urothelial carcinomas with a high tumor cell content (>70%) were selected for pyrosequencing.
Following optimization of primers for paraffin-embedded tissue, only one ASS1-positive tumor had an average methylation value of 45% that was greater than the threshold value of 40% (Supplementary Fig. S1 ). The remaining tumors with methylation values > 40% were all negative for ASS1 immunoexpression (p<0.001), validating the role of promoter methylation in ASS1 silencing in primary bladder cancer (Supplementary Table 3 ).
Next, we addressed the significance of epigenetic loss of ASS1 in bladder cancer by manipulating ASS1 in our panel of urothelial cancer cell lines. While ASS1 overexpression decreased the proliferation of 253J and UMUC-3 cells, ASS1 siRNA increased the proliferation of 5637 cells, consistent with a tumor suppressor role for ASS1 in urothelium (Fig. 2C) . We also observed a reciprocal relationship between ASS1 expression and cell invasion by performing matrigel invasion assays, confirming that ASS1 loss increased the invasiveness of urothelial tumor cells in vitro (Fig. 2D) . 
ASS1-methylated bladder cancer cell lines are sensitive to ADI-PEG20
To test the effect of arginine deprivation on bladder cancer cell line viability, we treated the panel of bladder cancer cell lines with the arginine depletor, ADI-PEG20.
All ASS1-negative cell lines were sensitive to ADI-PEG20 with the highly methylated lines 253J and UMUC-3 displaying the greatest sensitivity to arginine depletion; in contrast, the ASS1-positive cell lines 5637, RT112 and SCaBER were resistant to ADI-PEG20 (Fig. 3A) . Moreover, forced ASS1 overexpression in ASS1-negative cell lines reduced their sensitivity to ADI-PEG20, validating the role of ASS1 loss in mediating the synthetic lethal effect to arginine deprivation (Fig. 3B) .
ADI-PEG20 inhibits pyrimidine metabolism in ASS1-negative tumor cells
We proceeded to analyse the metabolic effects of ADI-PEG20 and confirmed a significant decrease in intracellular arginine with a corresponding increase in citrulline in ASS1-negative bladder cancer cells. Marked reductions in thymidine and increases in thymine and glutamine were also detected by LC/MS (Fig. 4A) . In contrast, ADI-PEG20 reduced arginine levels to a minor extent in the ASS1-positive RT112 control cell line while intracellular levels of thymidine, thymine, and glutamine were unaffected indicating a non-essential role for exogenous arginine. Due to these differential effects on intracellular thymidine, we interrogated gene pathways modulated by ADI-PEG20 identifying downregulation of the folate-dependent nucleotide synthesizing enzymes thymidylate synthase (TS) and dihydrofolate reductase (DHFR) specifically in ASS1-negative tumor cells (data not shown).
Marked suppression of DHFR and TS mRNA and protein was detected in all three ADI-sensitive bladder cancer cell lines whereas no effect was seen in the RT112 control cell line exposed to ADI-PEG20 (Fig. 4B-C) . We also analysed the thymidine salvage pathway, as a compensatory source of cellular thymidine upon suppression of de novo pyrimidine synthesis. Unexpectedly, ADI-PEG20 also reduced 3 H-thymidine uptake in the arginine-auxotrophic cell lines associated with downregulation of thymidine kinase 1 (TK1) (23) with no effect in RT112 control cells (Fig. 4D-E) .
Notably, co-treatment with MG132, a proteosome inhibitor that blocks protein degradation, abrogated the ADI-PEG20-induced suppression of TS and TK1 levels (Fig. 4F) . More generally, similar data on thymidine salvage and de novo synthesis pathways were obtained in a panel of ADI-treated ASS1-negative (methylated) mesothelioma cell lines ( Supplementary Fig S2) . Finally, we assessed whether in vivo imaging of thymidine uptake could provide an early biomarker of response to ADI-PEG20 therapy using UMUC-3 xenografts. Consistent with our in vitro studies, there was a 66% decrease in the maximum standardized uptake value (SUVmax) on [ 18 F]FLT-PET after 24h of ADI-PEG20 therapy (Fig. 4G ).
Enhanced effect of ADI-PEG20 and pemetrexed in bladder cancer
To exploit our findings in the clinic we employed the multitargeted antifolate pemetrexed, which blocks enzymes including TS and DHFR and is reported to have modest activity in bladder cancer (24) . High TS expression, in particular, has been linked to poor clinical outcome and resistance to antifolates in cancers of the bladder, lung, mesothelium and colon (25) (26) (27) (28) (29) . Moreover, bladder TMA analysis revealed that ASS1 loss was associated with a reciprocal increase in TS and DHFR expression -both linked to poor outcome for diseasespecific and metastasis-free survival -emphasizing the interdependence between arginine auxotrophy and modulation of nucleotide biosynthesis (Supplementary Fig. S3 cytotoxicity of pemetrexed in ASS1-negative tumor cells via modulation of folate-dependent enzymes. First, we showed that pemetrexed and ADI-PEG20 enhanced apoptosis compared with either agent alone by increasing PARP cleavage and annexin V binding in vitro in ASS1-methylated tumor cell lines (Fig. 5A-B) . Secondly, ADI-PEG20 significantly reduced tumor growth of the UMUC-3 cell line (p<0.001) in xenografted nude mice. While pemetrexed alone had no effect, the combination was more effective than ADI-PEG20 alone (p<0.05) (Fig. 5C-D) . Analysis of tumors from the xenograft studies confirmed reduced TS, DHFR and TK1 levels in ADI-PEG20-treated animals (Fig. 5E) . Finally, to validate our results we executed an deficiency. Exogenous arginine has also been shown to stimulate intestinal cell motility via activation of NO and focal adhesion kinase (FAK) signalling (32, 33) . In particular, arginine is a dominant amino acid modulator of mTOR, a nodal pathway that integrates cell growth, proliferation, invasion and metastasis of various cancers, including urothelial malignancy (34-36)_ENREF_42; moreover, arginine deprivation has been shown to repress mTOR and its downstream substrates p70 S6 kinase and 4E-BP1 in ASS1-negative cancer cells (6, 37) . Indeed, it is becoming clear that arginine deprivation has multiple effects on gene expression and that this is likely to be determined not only by cell type but also by the status of the ASS1 gene (38) .
The ADI-PEG20-induced suppression of the folate-dependent enzymes TS and DHFR and sensitization of ASS1-negative tumor cells to the cytotoxic effects of pemetrexed, provides a novel metabolic approach to retargeting cytotoxic chemotherapy (39) . Our results also validate the work of Cheng et al, who showed that the irreversible TS inhibitor 5-fluorouracil was more effective when combined with pegylated human arginase in a hepatocellular carcinoma xenograft (40) . It is noteworthy that the ADI-PEG20 and antifolate doublet has a wide therapeutic window in the xenograft studies. Moreover, our experience from an ongoing clinical trial of arginine depletion in mesothelioma (NCT01279967), includes a patient treated concurrently with ADI-PEG20 and the antifolate methotrexate for an unrelated condition; the combination was safe and led to a prolonged period of disease control (manuscript in preparation). CAN-13-1702 which there was no effect on TK1 expression and FLT-PET metabolic responses were not detected (41) . These and previous results using FDG tracers may be explained in part by the differential regulation of ASS1 promoter with HIF-1alpha-mediated repression in melanoma compared with epigenetic silencing identified in several other arginine auxotrophic cancers (9, 16, 42) .
Thus, arginine deprivation with ADI-PEG20 suppresses both the de novo and salvage pathways of nucleotide synthesis in ASS1-negative bladder cancer cells, which may be exploited for therapy and imaging, respectively (Fig. 6) . In addition to ADI-PEG20 modulating protein turnover as indicated by the MG132-mediated recovery of TS and TK1 enzymes, several other mechanisms may underlie the reduced levels of target proteins, including chemical attack by peroxynitrite, a potent oxidant and nitrating species generated by arginine deprivation (43) (44) (45) . More generally, the reciprocal relationship between thymidine and glutamine in ASS1-negative tumors reinforces several other preclinical approaches targeting amino acid utilization in cancer, including methionine, glycine and serine (46-49). Significantly, we observed that ASS1 downregulation was linked to the reciprocal upregulation of the serine biosynthetic pathway enzymes, PHGDH, PSAT1, and PSPH in bladder cancer (data not shown) and this warrants further evaluation in view of the important roles of serine in tumor cell proliferation and bioenergetics.
In conclusion, our studies linking the biology of arginine auxotrophic bladder cancer to adverse clinicopathological variables accentuate ASS1 loss as a novel biomarker for evaluation in patients with urothelial cancer. Specifically, targeted modulation of pyrimidine synthesis -via suppression of the de novo and salvage nucleotide pathways -using arginine-depleting drugs combined with antifolates has THF=tetrahydrofolate; PEM=pemetrexed.
